…
…

Finding your new normal

As a woman diagnosed with metastatic breast cancer (MBC), a lot may have changed—but a lot hasn’t.

IBRANCE® is the #1 prescribed, FDA-approved oral combination treatment for HR+, HER2- MBC.

IBRANCE® is the #1 prescribed, FDA-approved oral combination treatment for HR+, HER2- metastatic breast cancer.

HR+ = hormone receptor-positive
HER2- = human epidermal growth factor receptor 2-negative

INDICATIONS: IBRANCE is a prescription medicine used in adults to treat HR+, HER2- breast cancer that has spread to other parts of the body (metastatic) in combination with an aromatase inhibitor as the first hormonal based therapy in postmenopausal women or in men, or fulvestrant with disease progression following hormonal therapy.

Support and Information for Those Newly Diagnosed with Metastatic Breast Cancer

Support and Information for Those Newly Diagnosed with Metastatic Breast Cancer

An MBC diagnosis can be overwhelming and leave you feeling like your world has been turned upside down. Take a moment to hear how Diane, an IBRANCE Ambassador, coped with the news of her diagnosis. Also, explore the resources tailored for newly diagnosed MBC patients.

Ambassadors were asked to share their personal stories about IBRANCE. All content was accurate at the time of publication and may have since changed.

Ambassadors were asked to share their personal stories about IBRANCE. All content was accurate at the time of publication and may have since changed.

Turn to Pfizer Oncology Together to learn about financial assistance resources and get personalized support from one of our dedicated Care Champions.

CALL 1-844-9-IBRANCE (Monday–Friday 8 AM–8 PM ET)